Clinical trials
Heart Failure trials in Israel with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 3 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Unknown status | 13 |
| Recruiting | 5 |
| Terminated | 5 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sheba Medical Center | 6 |
| Medtronic Cardiac Rhythm and Heart Failure | 5 |
| Biotronik SE & Co. KG | 3 |
| Hadassah Medical Organization | 3 |
| Hillel Yaffe Medical Center | 3 |
| Abbott Medical Devices | 2 |
| Alleviant Medical, Inc. | 2 |
| Tel-Aviv Sourasky Medical Center | 2 |
| V-Wave Ltd | 2 |
| Bellerophon BCM LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Failure | 46 |
| Tachycardia | 3 |
| Edema | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Cardiomyopathy, Hypertrophic | 1 |
| Cardiovascular Abnormalities | 1 |
| HIV Infections | 1 |
| Heart Diseases | 1 |
| Heart Failure, Diastolic | 1 |
| Hypertension, Pulmonary | 1 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.